skip to Main Content

Molecular Characteristics of BRCA1/2 and PALB2 Mutations in Pancreatic Ductal Adenocarcinoma

Newsfeed image, light gray text on dark gray background
Poly-(ADP)-ribose polymerase (PARP) inhibitors are successfully used for treatment of BRCA-mutated (mut) breast cancers and are under extensive evaluation for BRCA- and PALB2-mutated pancreatic ductal adenocarcinoma (PDAC).

However, the optimal treatment regimen for BRCA/PALB2-mutated PDCA has yet to be established. Moreover, limited data are available on the association of BRCA/PALB2 gene alterations with other comutations and immunological biomarkers. Read more . . . 

Back To Top